低分子量肝素治疗进展型脑梗死及对血流变影响被引量：3

Study of hemorrheology on low molecular weight heparin in treatment of acute ischemic stroke

下载PDF

导出

摘要目的:探讨低分子量肝素对进展型脑梗死的疗效及血流变影响。方法:将80 例进展型脑梗死患者,随机分为治疗组40例,对照组40例。两组在治疗前后均行神经功能缺损评分和临床疗效评定,并观察其疗效及有关实验室指标,追踪随访1 年。结果:治疗组的有效率明显高于对照组,不良反应轻微,PLT、APTT无明显变化,但血流变指标明显下降,1年内复发率明显小于对照组。结论:低分子肝素治疗进展型脑梗死疗效肯定,对于减少复发亦有一定作用,并可改善血流变。 OBJECTIVE To investigate the curative effect and hemorrheology effect of low molecular weight heparin (LMWH) in the treatment of acute ischemic stroke.METHODS 80 cases of acute ischemic stroke patients were studied by comparison randomly.There were 40 cases in therapy group and 40 cases in comparison group.The patients then were evaluated according to neurologic deficit and disability,the patients were observed for one year.RESULTS The validity rate of therapy group was higher than comparison group.Relapse rate within one year was less than the comparison group.CONCLUSION LMWH in treatment of acute ischemic stroke is safe and effective.

作者朱明霞彭佳皮永前胡旸

机构地区广西柳州铁路中心医院

出处《中国医院药学杂志》 CAS CSCD 北大核心 2005年第4期322-324,共3页 Chinese Journal of Hospital Pharmacy

关键词低分子量肝素进展型脑梗死临床及血流变 LMWH acute ischemic stroke hemorrheology

分类号 R969.4 [医药卫生—药理学]

引文网络
相关文献

参考文献6

1脑卒中患者临床神经功能缺损程度评分标准（1995）[J].中华神经科杂志,1996,29(6):381-383. 被引量：15747
2朱明霞.低分子肝素治疗缺血性中风[J].血栓与止血学,2003,9(1):37-38. 被引量：9
3Barrowoliffe TW. Low molecular weight hparins[J]. Br J Haematol, 1995,90(1): 1～7.
4Green D, Hirsh J. Low molecular weight heparin: acritical analysis of clinical trials[J]. Pharmacol Rev, 1994,46 (1): 89～ 109.
5Rodprasert P. Low molecular weight heparin treatment in cerebral infarcions in 90 cases[J]. Cerebrovasc Dis, 1996,27 ( suppl ): 135.
6Koopman MM. Outpatient treatment of deep vein thrombosis with LMWH[J]. Wien Med Wochenschr, 1999,149 : 46.

二级参考文献16

1[1]Faredj, Walenga JM, Hoppensteadt D, et al. Comparative study on the in vitro and in vivo studise of seven low-molecular weight heparins. Haemostasis,1998,8:3～9.
2[2]Hirsh J, Levine MN, Low molecular weight heparin. Blood, 1992,79:1 ～ 6.
3[3]Barroweliffe TW. Low molecular weight heparin. Br J Heamatol, 1995,90(1):1～6.
4[5]Fareed J, Walenga J, Hoppensteadt D, et al. Chemleal and biological hererogeneity in low molecular weight heparins; implication for clinical use and seandrdization. Semin Thromb Hemost, 1989,15:440 ～ 444.
5[6]Melissari E, Parker CJ, Wilson NV, et al. Use of LMWH in pregnancy.Thromb Haemost, 1992,68:652 ～ 656.
6[7]Salznan EW, Rosenberg RD, Smith MH, et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest, 1980,65:64～ 68.
7[8]Blajchman MA, Young E. Ofosu FA. Effects of unfractionated heparin, dermatan sulfate and LMWH on vessel wall permeability in rabbits. Ann N Y Acad Sci, 1989,556:246 ～ 250.
8[9]Key R, Wongks, YU. Low molecular weight heparin for the treatment of acute ischemic stroke. N Engl J Med, 1995,333(24):1588 ～ 1594.
9[15]Green D, Hims J, Prins MH, et al. LMWH: a critical analysis of clinical trials. Pharmacol Rev, 1994,46:89 ～ 96.
10[16]Marbet GA. Low molecular weight heparin-1998 status. Schweiz Rundsch Med Prax, 1999,88: 802 ～ 808.